Titan Spine Raises Series B Financing

titan_spineTitan Spine, a Mequon, Wis.-based medical device surface technology company focused on developing innovative surface-enhanced spinal interbody fusion implants, closed a Series B financing of undisclosed amount.

Backers included Southlake Equity Group and other legacy investors.

The company will use the funds to grow through product line additions, sales team expansion, and accelerated research and development.

Led by Peter Ullrich, M.D., Chief Executive Officer and President, Titan Spine offers a full line of Endoskeleton® titanium implants that feature its proprietary nanoLOCK® surface technology, which was launched in October 2016 following FDA clearance in late 2014. The nanoLOCK® surface technology consists of a combination of roughened topographies at the macro, micro, and nano levels (MMN™) designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), downregulating inflammatory factors, and creating the potential for a faster and more robust fusion.

Titan Spine markets its devices in the U.S., Europe, and Australia through its sales force and a network of independent distributors.

FinSMEs

07/11/2018

Join the discussion